AUG 1 7 2004

OSPTO Form 1449 OU.S. Department of Commerce CADE TO THE STATEMENT				Attorney Docket No.		Serial No.		
INFORMATION DISCLOSURE STATEMENT				9000/2022 10/618,913				
				Applicant(s):. Faeldt, et al.				
				Filing Date: July 14, 2003			Group: 1638 1631	
U.S. PATENT DOCUMENTS								
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)	
MM	1.	6,500,617 B1	Dec. 31, 2002	Stemmer, et al.	435	6	Apr. 22, 1999	
MM	2.	5,716,831	Feb. 10, 1998	Whalon, et al.	435	19	May 24, 1995	
						,		
		-						
		,						
FOREIGN PATENT DOCUMENTS								
Examiner		Document No.	Publication	Country	Class	Subclass	Translation	
Initial			Date			_	YES	NO
	,							
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)								
MM	3.	Ciesla, et al.; "Mapping Effectiveness of Insecticide Treatments against Pandora Moth with Color-IR Photos"; (1984); Vol. 50, No. 1, pp. 73-79.						
MH	4.	Copy of International Search Report dated July 23, 2004 for PCT/WS 03/22033 majled H23/2004						
		majled 7/23/2004						
EXAMIN	ER	m. meler			DATE CONSIDERED 4/3/2006			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.								
**Copies of references not provided at the time of this submission.								

U.S. De Patent and Trader of TRADE Attorney Docket No. Serial No. 10/618,913 9000/2022 INFORMATION DISCLOSURE STATEMENT Applicant(s):. Faeldt, et al. Group: 1638 1631 Filing Date: July 14, 2003 U.S. PATENT DOCUMENTS Subclass Filing Date Examiner Patent No. Date Name Class (if appropriate) Initial FOREIGN PATENT DOCUMENTS Examiner Document No. Publication Country Class Subclass Translation Initial Date YES NO OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.) 1. Chan and Bonini; "Drosophila models of human neurodegenerative disease"; (2000); Cell Death and MM Differentiation; 7: 1075-1080. Feany and Bender; "A Drosophila model of Parkinson's disease"; (2000); Nature; 404: 394-398. 2. 3. Fernandez-Funez, et al.; "Identification of genes that modify ataxin-1-induced neurodegeneration"; (2000); Nature; 408: 101-106. 4. Fortini and Bonini; "Modeling human neurodegenerative diseases in Drosophila"; (2000); Trends Genet.; 16: 161-167. Jackson, et al.; "Polyglutamine-Expanded Human Huntington Transgenes Induce Degeneration of 5. Drosophila Photoreceptor Neurons"; (1998); Neuron; 21: 633-642. 6. Kazemi-Esfarjani and Benzer; "Genetic Suppression of Polyglutamine Toxicity in Drosophila"; (2000); Science; 287: 1837-1840. Warrick, et al.; "Expanded Polyglutamine Protein Forms Nuclear Inclusions and Causes Neural 7. Degeneration in Drosophila"; (1998); Cell; 93: 939-949. 8. Brand and Perrimon; "Targeted gene expression as a means of altering cell fates and generating dominant phenotypes"; (1993); Development; 118: 401-415. 9. Marsh, et al.; "Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila; (2000); Hum. Mol. Genet.; 9: 13-25. DATE CONSIDERED 4/3/2006 us wills **EXAMINER** *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

7

**Copies of references not provided at the time of this submission.